-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $10.26
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $10.26
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $10.26, but opened at $10.67. Nurix Therapeutics shares last traded at $10.75, with a volume of 316 shares changing hands.
Analysts Set New Price Targets
Several research firms have recently weighed in on NRIX. Morgan Stanley began coverage on Nurix Therapeutics in a research report on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 target price on the stock. HC Wainwright decreased their target price on Nurix Therapeutics to $53.00 in a research report on Thursday, October 13th. Finally, SVB Leerink decreased their target price on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $32.90.
Get Nurix Therapeutics alerts:Nurix Therapeutics Price Performance
The stock has a market cap of $533.24 million, a price-to-earnings ratio of -3.05 and a beta of 1.63. The firm has a fifty day moving average of $11.93 and a 200 day moving average of $13.70.
Institutional Investors Weigh In On Nurix Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Nurix Therapeutics by 11.0% during the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after acquiring an additional 367,743 shares during the last quarter. State Street Corp increased its stake in Nurix Therapeutics by 9.2% during the third quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after acquiring an additional 195,453 shares during the last quarter. Vanguard Group Inc. increased its stake in Nurix Therapeutics by 2.3% during the third quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after acquiring an additional 49,370 shares during the last quarter. Bain Capital Life Sciences Investors LLC increased its stake in Nurix Therapeutics by 41.9% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 1,822,883 shares of the company's stock worth $23,096,000 after acquiring an additional 538,570 shares during the last quarter. Finally, FMR LLC increased its stake in Nurix Therapeutics by 59.6% during the second quarter. FMR LLC now owns 1,790,655 shares of the company's stock worth $22,688,000 after acquiring an additional 668,632 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company's stock.Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Featured Articles
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $10.26, but opened at $10.67. Nurix Therapeutics shares last traded at $10.75, with a volume of 316 shares changing hands.
Nurix Therapeutics, Inc.（纳斯达克股票代码：NRIX — 获取评级）在周二交易前出现了空白。该股此前收于10.26美元，但开盘价为10.67美元。Nurix Therapeutics股票最后一次交易价格为10.75美元，成交量为316股。
Analysts Set New Price Targets
分析师设定了新的价格目标
Several research firms have recently weighed in on NRIX. Morgan Stanley began coverage on Nurix Therapeutics in a research report on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 target price on the stock. HC Wainwright decreased their target price on Nurix Therapeutics to $53.00 in a research report on Thursday, October 13th. Finally, SVB Leerink decreased their target price on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $32.90.
几家研究公司最近对NRIX进行了权衡。摩根士丹利在10月11日星期二的一份研究报告中开始报道Nurix Therapeutics。他们对该股发布了 “同等权重” 的评级和11.00美元的目标价格。HC Wainwright在10月13日星期四的一份研究报告中将Nurix Therapeutics的目标价格下调至53.00美元。最后，SVB Leerink在12月13日星期二的一份研究报告中将Nurix Therapeutics的目标价格从37.00美元下调至28.00美元，并对该股设定了 “跑赢大盘” 的评级。一位投资分析师对该股进行了持有评级，七位投资分析师对该股给予了买入评级。根据Marketbeat.com的数据，Nurix Therapeutics目前的平均评级为 “适度买入”，平均目标价为32.90美元。
Nurix Therapeutics Price Performance
Nurix Therapeutics
The stock has a market cap of $533.24 million, a price-to-earnings ratio of -3.05 and a beta of 1.63. The firm has a fifty day moving average of $11.93 and a 200 day moving average of $13.70.
该股的市值为5.3324亿美元，市盈率为-3.05，beta值为1.63。该公司的五十天移动平均线为11.93美元，200天移动平均线为13.70美元。
Institutional Investors Weigh In On Nurix Therapeutics
机构投资者对 Nurix Therapeutics 进行了权衡
Nurix Therapeutics Company Profile
Nurix Therapeutics
(Get Rating)
（获取评分）
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Nurix Therapeutics, Inc是一家生物制药公司，专注于发现、开发和商业化用于治疗癌症和免疫疾病的小分子疗法。该公司开发了 NX-2127，一种用于治疗复发或难治性 B 细胞恶性肿瘤的口服布鲁顿酪氨酸激酶 (BTK) 降解剂；NX-5948，一种用于治疗复发或难治性 B 细胞恶性肿瘤和自身免疫性疾病的口服 BTK 降解剂；NX-1607，一种口服 Casitas B 系淋巴瘤 proto-oncogene-B (CBL-B) 抑制剂免疫肿瘤学适应症。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 免费获取 StockNews.com 关于 Nurix Therapeutics (NRIX) 的研究报告
- 升级后 Bloom Energy 会加电，值得冒险吗？
- 为什么 Hershey 是一只甜蜜的衰退股票
- 亚马逊股票会在 2023 年为投资者带来收益吗？
- 分析师将卡车运输情绪向前转移
- 这些机构预订波音的航班
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Nurix Therapeutics 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Nurix Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧